08.31.17
Daiichi Sankyo Co., Ltd. has elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories, forgoing further development of Charleston’s hydrocodone products, including CL-108 (hydrocodone, acetaminophen, promethazine) and will be returning all rights to those products to Charleston.
"During a recent portfolio and U.S. market review, Daiichi Sankyo made the strategic decision to refocus our commercial efforts on our current product line in the U.S. pain franchise as well as other molecules in our pipeline," said Ken Keller, president, Administrative and Commercial, Daiichi Sankyo, Inc. "We would like to thank Charleston Laboratories for its partnership and commitment to patients suffering with acute pain and opioid-induced nausea and vomiting. Daiichi Sankyo remains dedicated to bringing innovative medicines to patients and will continue to explore future opportunities that support our corporate strategy to expand our business and achieve long-term growth."
Daiichi Sankyo Co., Ltd. will take an impaired loss of approximately $250 million U in the 2Q17, reflecting payments made to Charleston Laboratories under the terms of the agreement.
"During a recent portfolio and U.S. market review, Daiichi Sankyo made the strategic decision to refocus our commercial efforts on our current product line in the U.S. pain franchise as well as other molecules in our pipeline," said Ken Keller, president, Administrative and Commercial, Daiichi Sankyo, Inc. "We would like to thank Charleston Laboratories for its partnership and commitment to patients suffering with acute pain and opioid-induced nausea and vomiting. Daiichi Sankyo remains dedicated to bringing innovative medicines to patients and will continue to explore future opportunities that support our corporate strategy to expand our business and achieve long-term growth."
Daiichi Sankyo Co., Ltd. will take an impaired loss of approximately $250 million U in the 2Q17, reflecting payments made to Charleston Laboratories under the terms of the agreement.